title: Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.
abstract: Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this effect was not comparable to observations for an alisporivir-susceptible virus, the flavivirus tick-borne encephalitis virus. Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses pathogenic to humans.
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Abhilash I
authors: AI
authors: Chiramel
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Logan
authors: L
authors: Banadyga
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Jonathan D
authors: JD
authors: Dougherty
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Saskatoon, Canada.
authors: Darryl
authors: D
authors: Falzarano
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Cynthia
authors: C
authors: Martellaro
authors: Novartis Pharma, Basel, Switzerland.
authors: Dominique
authors: D
authors: Brees
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana Department of Medical Microbiology and Immunology, College of Medicine, University of Toledo Health Science Campus, Ohio.
authors: R Travis
authors: RT
authors: Taylor
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Hideki
authors: H
authors: Ebihara
authors: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana.
authors: Sonja M
authors: SM
authors: Best
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D000998:Antiviral Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004196:Disease Outbreaks; D029043:Ebolavirus / Q000187:drug effects*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D014779:Virus Replication
chemical_list: D000998:Antiviral Agents; D016572:Cyclosporine; C499715:alisporivir
keywords: Ebola virus; alisporivir; antivirals; cyclophilin A; flavivirus